Clinical Trial: A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815575) titled 'A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.' on Jan. 20.

Brief Summary: This is a multi-centre, two-part, open-label, phase 1, first in human study of multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) in adult patients with advanced solid tumours where an anthracycline may be considered as a treatment option / or is indicated.

The study will consist of Part 1 - dose-escalation, to determine the maximum tolerated combination ...